STOCK TITAN
  1. Home
  2. News
  3. GH

Guardant Health Inc - GH STOCK NEWS

Welcome to our dedicated news page for Guardant Health (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Guardant Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Guardant Health's position in the market.

News
FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
Rhea-AI Summary
Guardant Health, Inc. (Nasdaq: GH) is set to have the FDA Advisory Panel review its Shield™ blood test for colorectal cancer screening on May 23, 2024. The company aims to present clinical data from its ECLIPSE study, highlighting the potential of the Shield test to provide a more convenient and effective screening option for early detection of colorectal cancer, increasing treatment opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024
Rhea-AI Summary
Guardant Health, a leading precision oncology company, will report its first quarter 2024 financial results on May 9, 2024, after market close. The company's management will host a webcasted conference call, providing investors with an opportunity to listen to the live audio on the company's website. The webcast will also be available for replay after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
Rhea-AI Summary
Guardant Health presents new data on epigenomic analysis and methylation sequencing at the 2024 AACR Annual Meeting, showcasing the performance of Guardant Reveal in detecting residual disease in early-stage breast cancer without tissue samples. The Guardant Infinity platform offers insights for cancer care, from histologic subtyping to predicting adverse events, enabling personalized treatment strategies and expanding patient eligibility for clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.24%
Tags
conferences
News
Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine
Rhea-AI Summary
Guardant Health, Inc. announces successful results from the ECLIPSE study showing the effectiveness of its Shield blood test in detecting colorectal cancer. The study reveals 83% sensitivity in detecting individuals with CRC and 88% sensitivity in detecting Stages I-III. Shield's potential FDA approval could revolutionize CRC screening, offering a convenient and accurate alternative to traditional methods.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
none
-
News
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Guardant Health, Inc. announced the granting of restricted stock units and stock options to new non-executive employees under the 2023 Employment Inducement Incentive Award Plan. The awards were made to 82 employees and one new Chief People Officer, Terilyn Juarez Monroe. The RSUs and stock options were granted as inducements for joining Guardant, with specific vesting conditions. The stock options have an exercise price of $20.14 per share, reflecting the closing price on February 26, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.58%
Tags
none
-
News
New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap
Rhea-AI Summary
Guardant Health, Inc. releases survey findings indicating that blood-based testing could revolutionize colorectal cancer screening, potentially closing the screening gap for millions of Americans. The survey highlights the preference for more convenient and pleasant screening options among patients and physicians, emphasizing the potential impact of blood-based tests like the Shield™ test in increasing screening adherence rates and saving lives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
none
News
Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
Rhea-AI Summary
Guardant Health, Inc. (GH) reports a 25% revenue growth in 2023 driven by a 39% increase in clinical volume. Full year 2024 revenue is expected to range from $655 to $670 million. The company achieved cash flow breakeven in its Therapy Selection business in 2023, ending the year with $1.2 billion in cash, cash equivalents, and marketable debt securities. Guardant Health made progress with FDA on its Shield PMA submission and anticipates launching its Shield IVD test in 2024 after FDA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.8%
Tags
earnings
-
News
Guardant Health to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Guardant Health, Inc. (GH) will participate in investor conferences, including Citi 2024 Unplugged Medtech and Life Sciences Access Day and TD Cowen 44th Annual Health Care Conference. Interested parties can access live and archived webcasts on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
conferences
-
News
Guardant Health to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
Rhea-AI Summary
Guardant Health, Inc. (Nasdaq: GH) will report financial results for Q4 and full year 2023 on February 22, 2024. The company will webcast the conference call, with live audio available on their website. Investors can access the archived webcast for replay after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
conferences earnings
News
Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence
Rhea-AI Summary
Guardant Health, Inc. will present interim data from the COSMOS study supporting the use of Guardant Reveal to predict disease recurrence in patients with early-stage colon cancer at the ASCO 2024 Gastrointestinal Cancers Symposium. The test is highly specific and predictive for recurrence, without dependence on a tissue sample.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
conferences
Stock GH logo
Guardant Health Inc

Nasdaq:GH

GH Rankings

#1806 Ranked by Market Cap
#4656 Ranked by Stock Gains
N/A Ranked by Dividends

GH Stock Data

2.22B
116.64M
4.15%
92.14%
6.28%
Dental Laboratories
Manufacturing
Link
United States
Palo Alto

About GH

we believe conquering cancer is a big data problem. that’s why we built the world’s leading comprehensive liquid biopsy. this non-invasive tool for accessing and sequencing tumor dna is used by thousands of oncologists to help tens of thousands of advanced cancer patients. we believe the boom in cancer data acquisition we helped launch will drive important discoveries and new products. we’re working on some exciting ones, including in early detection, where the impact on patients can be profound. we’ve raised more than $500 million from investors including sequoia capital, khosla ventures, orbimed, and softbank.